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Abstract
Background: Alzheimer’s disease and related dementias (ADRD) impact a woman’s life expectancy and her ability
to participate in medical decision-making about breast cancer screening, necessitating the involvement of family
caregivers. Making decisions about mammography screening for women with ADRD is stressful. There are no data
that suggest that breast cancer screening helps women with ADRD live longer or better. Decision aids may improve
the quality of decision-making about mammography for ADRD patients and may inform family caregivers about the
risks, benefits, and need for decision-making around mammography screening.
Methods/design: The Decisions about Cancer Screening in Alzheimer’s Disease (DECAD) trial, a randomized controlled
clinical trial, will enroll 426 dyads of older women with ADRD (≥75 years) and a family caregiver from clinics and primary-
care practices in Indiana to test a novel, evidence-based decision aid. This decision aid includes information about the
impact of ADRD on life expectancy, the benefit of mammograms, and the impact on the quality of life for older women
with ADRD. Dyads will be randomized to receive the decision aid or active control information about home safety. This
trial will examine the effect on the caregiver’s decisional conflict (primary outcome) and the caregiver’s decision-making
self-efficacy (secondary outcome). A second follow-up at 15 months will include a brief, semi-structured interview with
the caregiver regarding the patient’s experience with mammograms and decision-making about mammograms. At the
same time, a review of the patient’s electronic medical record (EMR) will look at discussions about mammography with
their primary-care physician and mammogram orders, receipt, results, and burden (e.g., additional diagnostic procedures
due to false-positive results, identification of an abnormality on the screening exam but further work-up declined, and
identification of a clinically unimportant cancer). A third follow-up at 24 months will extract EMR data on mammogram
orders, occurrences, results, and the burden of mammograms.
Discussion: We hypothesize that caregivers who receive the decision aid will have lower levels of decisional conflict and
higher levels of decision-making self-efficacy compared to the control group. We also hypothesize that the DECAD
decision aid will reduce mammography use among older women with ADRD.
Trial registration: Clinical Trials Register, NCT03282097. Registered on 13 September 2017.
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Background
The incidence of both Alzheimer’s disease and related de-
mentias (ADRD) and breast cancer increases with age [1, 2];
thus, many older women with ADRD are faced with ques-
tions about breast cancer screening [3, 4]. Some current rec-
ommendations for breast cancer screening use life
expectancy (e.g., age, functional status, and co-morbidity
status) to form their guidelines on the clinical appropriate-
ness of mammography [5–12] (http://www.choosingwise-
ly.org/clinician-lists/amda-cancer-screenings-if-life-expectan-
cy-less-than-10-years/). The data suggest that women need a
life expectancy of 10 years to have a mortality benefit from
mammography screening. Some guidelines specifically
recommend not screening women with a life expectancy
<10 years [5, 6, 8, 9, 11–15] (http://www.choosingwisely.org/
clinician-lists/society-general-internal-medicine-cancer-scree-
ning-in-adults-with-life-expectancy-less-than-10-years/) and
note that screening beyond 75 years of age should be
approached with caution due to the increased burden and
risk of overdiagnosis and overtreatment [7, 8, 11, 16]. The
average life expectancy of older women with ADRD is
<10 years [16–21], and approximately 26% of women with
ADRD (over 800,000 in the U.S. population) receive
screening mammograms annually at an average annual cost
of $32 million [2, 22] (http://www.choosingwisely.org/clini-
cian-lists/society-general-internal-medicine-cancer-screenin-
g-in-adults-with-life-expectancy-less-than-10-years/). While
some women with ADRD discontinue mammograms as they
age or become more impaired, many continue, even fol-
lowing a serious health event, such as a myocardial infarc-
tion or stroke, or well beyond the time that it is clinically
beneficial [3, 4, 15, 19, 22–25] (http://www.choosingwise-
ly.org/clinician-lists/amda-cancer-screenings-if-life-expec-
tancy-less-than-10-years/).
The risks, burdens, and harms of mammography
screening for older women with ADRD are both physical
and psychological and encompass medical interventions
often referred to as the treatment cascade [26, 27].
Screening women with ADRD can potentially put them
at risk of physical and psychological harm as a result of
overdiagnosis, overtreatment, additional tests due to
false positives, and the identification of a clinically unim-
portant cancer [4, 25, 28, 29]. Women with ADRD may
also experience additional burdens because of their cog-
nitive impairment. For example, these women may not
understand the purpose of the test or become confused
or agitated when waiting or having the test conducted
[22, 25, 30, 31]. The test itself has been reported by care-
givers as more burdensome for older women with
ADRD [4, 32]. Conversely, while mammography screen-
ing may not help older women with ADRD live longer, it
may help find breast cancers earlier when they are easier
to treat [33]. Therefore, it is important that women with
ADRD and their caregivers have all the pertinent
information needed to make an informed decision about
screening.
Because ADRD can impact a woman’s ability to par-
ticipate in her medical decision-making about breast
cancer screening [31, 34, 35], family and non-paid friend
caregivers (hereafter referred to as caregivers) are fre-
quently involved in making decisions about mammog-
raphy [3, 4, 32, 36]. Caregivers report stress, decisional
conflict, and a lack of knowledge about and confidence
in making mammography decisions for their relative
with ADRD [3, 4, 28, 37], which can increase their bur-
den [35, 36, 38]. Additionally, they cite concerns that
screening tests may continue due to scheduled re-
minders or habit, even when the test becomes more bur-
densome and less beneficial to the patient [4, 28].
Informational tools, such as decision aids, that describe
the proximate risks and distant benefits [39] of mam-
mography based on an individual’s life expectancy, co-
morbidity status, and personal preference may reduce
caregiver decisional conflict and decision-making
self-efficacy, and facilitate screening discussions between
ADRD caregivers and primary-care physicians (PCPs)
[40–46]. For example, Hanson et al. [43] created and
tested a decision aid for surrogates of nursing home resi-
dents with ADRD to support caregiver decisions about
feeding options. They found that a decision aid de-
creased caregivers’ decisional conflict, improved their
knowledge scores, and enhanced discussions with pro-
viders about feeding options. These studies support the
potential impact of decision aids on improved ADRD
patient and caregiver outcomes.
To fill the gap in providing ADRD patients and their
caregivers with decision support about mammography
screening, we created a new decision aid that is written
for ADRD caregivers and is specific for older women
with ADRD. The design of this decision aid was in-
formed by a decision aid on mammography screening
for older women without dementia developed by Dr.
Mara Schonberg (co-investigator) [47, 48], our pilot
work [28, 32], and critera established for the develop-
ment and testing of evidence-based decision aids [49].
Our research team is now conducting a randomized
controlled trial, Decisions about Cancer Screening in
Alzheimer’s Disease (DECAD), to test if this new
evidence-based decision aid can improve the quality of
decision-making about mammography in older women
with ADRD. The primary outcome is a caregiver-
assessed measure of decisional conflict about breast
cancer screening. Secondary outcomes include other
measures of decision quality and utilization of mammo-
grams. We hypothesize that caregivers of patients who
use the decision aid will have lower levels of decisional
conflict as measured by the decisional conflict scale
(DCS) and higher levels of decision-making self-efficacy
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as measured by the decision self-efficacy scale (DSE)
compared to the control group. We also hypothesize
that the DECAD decision aid will reduce mammography
use among older women with ADRD within the
follow-up period of 24 months.
Methods/design
DECAD study design
The DECAD study is a multi-center randomized con-
trolled trial of an evidence-based mammography screen-
ing decision aid for older women with ADRD and their
caregivers. It will enroll 426 ADRD patient/caregiver
dyads; 213 dyads will be randomized to receive the deci-
sion aid and 213 dyads will receive an active control in
the form of a pamphlet on home safety. This study
protocol follows the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Guide-
lines (Additional file 1). The trial will be conducted and
reported according to the reporting of pragmatic trials:
an extension of the Consolidated Standards of Reporting
Trials (CONSORT) Statement. The study has been ap-
proved by the institutional review board of Indiana Uni-
versity (1501278953A022). The DECAD trial is
registered with clinicaltrials.gov (NCT03282097).
Setting and study population
Patient/caregiver dyads for DECAD will be recruited
from the following sites, which serve diverse populations
of patients throughout Indiana, USA: the Indiana Uni-
versity Alzheimer Disease Center; the Aging Brain Care
Program at Eskenazi Health (EH); primary-care sites at
EH; the Departments of Medicine, Neurology, and
Psychiatry at Indiana University Health (IUH); primary-
care sites affiliated with IUH; support groups for ADRD
caregivers hosted by the Alzheimer’s Association-Greater
Indiana Chapter; and other organizations that support
persons with ADRD. Recruitment in the clinical sites
will occur via the Indiana University Practice-Based Re-
search Network (IU-PBRN), which covers research re-
cruitment in all primary-care practices affiliated with EH
and IUH [50]. All primary-care practices affiliated with
EH are federally qualified health centers. The Aging
Brain Care Program combines a specialty clinic and
home-based dementia collaborative care program serv-
ing patients with ADRD and other cognitive disorders.
In the state of Indiana, IUH has more than 200
primary-care providers and 150,000 patients, and it re-
ceives 330,000 annual primary-care visits. The Indiana
University Alzheimer Disease Center is one of 32 centers
funded by the National Institute on Aging that support
ADRD research in the country. Recruitment via the Alz-
heimer’s Association support groups and other commu-
nity organizations will be facilitated through the Indiana
University Center for Aging Research Community En-
gagement Initiative [51].
Eligibility
The target population is dyads of caregivers of women
aged 75 years or older with a diagnosis of ADRD and
the woman with ADRD. The eligibility of patients will
be established through screening the Indiana Network
for Patient Care (INPC) database or the local practice
medical record. For caregivers, assessments will be con-
ducted by research assistants face-to-face or via the
telephone.
Inclusion criteria
The following inclusion criteria apply to the patients: fe-
male, ≥75 years, at least one mammogram in the past 5
years, a primary-care visit scheduled in the next
12 months, diagnosis of ADRD as determined by the
ICD-10 code in their ambulatory electronic health rec-
ord, ability to provide informed consent or assent, and
ability to communicate in and read English. Determin-
ation of capacity for the patient to consent is assessed
prior to obtaining consent by trained study personnel
using the teach-back method with questions specific to
the risks and benefits of participating in the study [52].
The caregiver inclusion criteria are as follows: 18 years
or older; primary family, friend, or non-paid caregiver of
the patient identified by the patient, self-identified, or
listed as the primary caregiver in the electronic medical
record (EMR) or registry; ability to provide informed
consent; and ability to communicate in and read English.
Exclusion criteria
The following exclusion criteria apply to the patients:
permanent resident of a nursing facility; had a mammo-
gram in the past 9 months; primary-care visit scheduled
is the first visit with the PCP; has already decided to stop
getting mammograms; history of atypical ductal hyper-
plasia, lobular carcinoma in situ, ductal carcinoma in
situ, or other invasive breast cancer in the past five
years; diagnosis of mild cognitive impairment or serious
mental illness, such as bipolar disorder or schizophrenia,
as determined by the ICD-10 code. The caregiver exclu-
sion criteria are as follows: less than a 7th grade educa-
tion; has already decided that the patient will stop
getting mammograms; and diagnosis of ADRD or a ser-
ious mental illness, such as bipolar disorder or schizo-
phrenia, as determined by the ICD-10 code.
Recruitment
Dyads will be recruited throughout the state of Indiana
using the IU-PBRN, the local EMR systems, research
registries at Indiana University, and advertising. Data
generated by the IU-PBRN will be collected and stored
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in the INPC, which is the central Indiana Regional
Health Information Exchange [53]. Given that not all pa-
tients will have a caregiver living with them during the
study and that caregiving arrangements will vary, we will
identify the person who is the primary caregiver or in-
formant and ensure that they attend the patient’s next
primary-care visit. Rolling enrollment will take place
over 36 months with a planned average monthly enroll-
ment of 11 or 12 dyads.
Data managers of the INPC and local health-care sys-
tems will identify eligible patients based on the inclusion
criteria (i.e., any woman ≥75 years of age with a diagno-
sis of ADRD who has received a mammogram in the
past 5 years, who does not have a 5-year history of
breast cancer, and for whom it is not recorded in her
EMR that she has decided to stop mammography). The
details of eligible patients recruited from a clinical site
will be provided to the patient’s PCP. Following approval
by the PCPs, study personnel will approach eligible dyad
participants via the telephone to confirm interest and
eligibility and to obtain informed consent. Those being
recruited from research registries will be contacted dir-
ectly and without prior approval from their PCP since
they have already provided consent to be contacted for
research. We will contact the primary caregiver for each
eligible woman. Caregivers will be eligible if they are the
only or are one of the primary caregivers for the patient
and intend to accompany the patient to the next clinic
visit.
Randomization
The unit of randomization will be the patient/caregiver
dyad. Dyads will be randomly assigned in a 1:1 ratio to
one of two groups (mammogram decision aid or pamph-
let on home safety) and stratified by recruitment site to
control for institutional effects and the styles of different
PCPs.
Study statisticians will use a computer-generated
randomization scheme to assign dyads, rather than pro-
viders or clinics, to the intervention or control group to
minimize the effects of unmeasured case mix differences
and clinic-level clustering. Based on descriptive data
from the recruitment sites, the large number of individ-
ual recruitment sites, and the total number of PCPs, the
risk of spillover from having participating dyads interact
or PCPs treat patients who have caregivers in both the
intervention and control group is likely to be small.
Additionally, we found from our pilot work that inter-
vention materials are unlikely to be shared with others,
which leaves the control dyads unexposed [28].
Description of the intervention
Based on a mammography screening decision aid de-
signed by Dr. Schonberg [47, 48], the investigative team
designed a decision aid that is specific for older women
with ADRD and their caregivers [28, 32]. The wording,
context, and content of the decision aid reflect the litera-
ture on the risks and benefits of mammography screen-
ing for older women with ADRD [24, 45, 49, 54].
Specifically, the decision aid is written at a 6th grade
reading level and includes text and visual information
on: (1) breast cancer risk factors for women >75 years,
(2) health and life expectancy with ADRD, (3) likely out-
comes if screened and not screened with mammography,
(4) competing mortality risks, (5) breast cancer treat-
ments, (6) an acknowledgment of the emotions of care-
givers who participate in medical decision-making for
their loved one with ADRD, and (7) tips on how to talk
with the patient’s PCP about mammograms.
Description of the control
To reduce response bias and to compensate for the time
and attention required by the intervention group to read
the decision aid, caregivers in the control arm will be
given a two-page pamphlet on home safety for older
adults developed by the Foundation for Health in Aging of
the American Geriatrics Society. The pamphlet contains
tips about important actions older adults can take to safe-
guard themselves from falls, poisoning, bathroom hazards,
abuse, fire, and other home-related hazards [55].
We do not plan any intervention for the PCPs because
we do not want to change their usual behavior. However,
if PCPs request a copy of the educational materials then
we will email them a copy of the home safety pamphlet
following the post PCP assessment.
Delivery of intervention and assessments
Both members of the dyad will receive the decision aid or
pamphlet on home safety by mail following enrollment,
baseline data collection, and randomization (Fig. 1). A let-
ter accompanying the decision aid or pamphlet on home
safety requests that the caregiver review the decision aid
or pamphlet on home safety on their own and with the pa-
tient before the patient’s next PCP visit. A trained research
assistant will then meet with the dyad together and
in-person 0–2 days prior to the index PCP visit. At that
encounter, the research assistant will ensure that the care-
giver has reviewed all pages of the decision aid or pamph-
let on home safety and, if needed, supply a second copy if
either member of the dyad did not bring it with them. The
research assistant will not discuss the content of the deci-
sion aid or pamphlet on home safety with the caregiver;
they will simply ensure that they have read it in its entirety
before the patient’s PCP visit. If the caregiver or patient
has any questions about the content of the decision aid or
pamphlet on home safety, the research assistant will en-
courage them to ask the patient’s PCP or to discuss the
materials with the PCP. If the index PCP visit is canceled,
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the dyad will remain enrolled and will be followed until
the visit is rescheduled. If the visit is never rescheduled
during the study window, the dyad will remain in the
study in their assigned group for an intention-to-treat
analysis.
The follow-up with the dyad after the PCP visit (con-
ducted in phone or in-person by a research assistant)
will ideally be scheduled immediately after the PCP visit,
but no later than 5 days after the PCP visit to measure
post-visit outcomes. Caregiver assessments at this time
include decisional conflict, decision-making self-efficacy,
their role in decision-making, their intentions for
whether the patient will be screened, their knowledge of
mammography screening in older women with ADRD,
and what they discussed about mammography with the
PCP at the index visit (continue, discontinue, or no deci-
sion). Patient assessments at the post-visit follow-up in-
clude their role in decision-making and their intentions
for whether they will be screened.
A second follow-up at 15 months will be conducted and
will include a brief semi-structured interview with a
trained research assistant. At this time, patient data will be
extracted from their EMR on: what they discussed about
mammography with the PCP at any visit since the index
visit (continue, discontinue, or no decision), orders for
mammograms, receipt of a mammogram, data on the
mammogram results if received, and data on the burden
of mammograms (e.g., additional diagnostic procedures
due to false-positive results, identification of an abnormal-
ity on the screening exam but further work-up declined,
identification of a clinically unimportant cancer, and docu-
mentation of depressive symptoms, anxiety, or pain re-
lated to the screening experience). The semi-structured
interviews will assess the caregiver’s perceptions about the
patient’s experience with mammograms, if received, and
about any decisions that they and the patient have made
about mammograms.
The third and final 24-month follow-up of EMR data
will be conducted to measure mammogram orders, re-
ceipt, results, and burden.
Primary and secondary outcome measures
All outcomes and measures for the DECAD trial are sum-
marized in Table 1. The primary outcome will be assessed
using the DCS to determine the impact of the decision aid
on caregivers’ decisional conflict about whether their rela-
tive with ADRD should receive a mammography. The
DCS includes 16 questions regarding a medical decision
that they have made or that they are about to make [56].
It is a validated and widely accepted measure of decision
quality that has been used in previous studies of decision
aids intended for ADRD caregivers [57, 58]. On average,
the DCS takes 5–7 min to complete. Test-retest correla-
tions and Cronbach alpha coefficients exceed 0.78, and
tests of predictive validity found that for every one unit in-
crease in the DCS, people were 59 times more likely to
change their mind, 23 times more likely to delay their de-
cision, and 5 times more likely to express regret about a
decision [56, 59–62].
Secondary outcome measures include decision-making
self-efficacy, receipt of a mammogram, caregiver know-
ledge about mammograms for older women with ADRD,
and the patient’s and caregiver’s role in the mammog-
raphy decision. To measure decision-making self-effi-
cacy, we will use the DSE, a validated 11-item
instrument that measures how confident the respondent
Fig. 1 Flowchart of study participation and intervention
Fowler et al. Trials          (2018) 19:678 Page 5 of 12
Ta
b
le
1
O
ut
co
m
es
an
d
m
ea
su
re
s
O
ut
co
m
es
O
ut
co
m
e
m
ea
su
re
s
D
es
cr
ip
tio
n
Sc
or
in
g
W
he
n
So
ur
ce
Pr
im
ar
y
ou
tc
om
e
D
ec
is
io
na
lc
on
fli
ct
16
-it
em
s
on
a
1–
5-
po
in
t
Li
ke
rt
sc
al
e.
M
ea
su
re
s
un
ce
rt
ai
nt
y
ar
ou
nd
a
de
ci
si
on
,
w
he
th
er
th
ey
fe
el
s
in
fo
rm
ed
,c
le
ar
ab
ou
t
th
ei
r
pe
rs
on
al
va
lu
es
,a
nd
su
pp
or
te
d
in
th
ei
r
de
ci
si
on
-m
ak
in
g
[5
5]
Sc
or
es
ra
ng
e
0–
10
0;
lo
w
er
sc
or
es
in
di
ca
te
le
ss
co
nf
lic
t
Ba
se
lin
e,
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
Se
co
nd
ar
y
ou
tc
om
es
D
ec
is
io
n-
m
ak
in
g
se
lf-
ef
fic
ac
y
11
ite
m
s
on
a
5-
po
in
t
Li
ke
rt
sc
al
e.
M
ea
su
re
s
of
se
lf-
co
nf
id
en
ce
or
be
lie
f
in
th
ei
r
ab
ili
ty
to
m
ak
e
de
ci
si
on
s
[6
2]
Sc
or
es
ra
ng
e
0–
10
0;
hi
gh
er
sc
or
es
in
di
ca
te
m
or
e
se
lf-
ef
fic
ac
y
Ba
se
lin
e,
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
In
te
nt
io
n
to
be
sc
re
en
ed
Th
re
e
ite
m
s.
Tw
o
ite
m
s
as
se
ss
pr
op
en
si
ty
to
ge
t
pe
rs
on
w
ith
A
D
RD
sc
re
en
ed
.O
ne
ite
m
as
ks
ho
w
m
an
y
m
or
e
m
am
m
og
ra
m
s
th
ey
th
in
k
th
e
pa
tie
nt
w
ill
ge
t
Ye
s
vs
.t
ho
se
w
ho
ar
e
un
su
re
or
pl
an
no
t
to
be
sc
re
en
ed
Ba
se
lin
e,
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
;
pa
tie
nt
re
po
rt
ed
Re
ce
ip
t
of
sc
re
en
in
g
D
is
cu
ss
io
n
w
ith
ca
re
gi
ve
r
Ye
s
vs
.n
o
15
-m
on
th
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
Re
vi
ew
pr
im
ar
y-
ca
re
no
te
s,
ra
di
ol
og
y
re
po
rt
s,
an
d
do
cu
m
en
ta
tio
n
on
sc
re
en
in
g
an
d
pr
ev
en
tiv
e
ca
re
;c
ar
eg
iv
er
re
po
rt
.
Ye
s
vs
.n
o
15
-
an
d
24
-m
on
th
fo
llo
w
-u
ps
Pa
tie
nt
EM
R
Kn
ow
le
dg
e
16
-it
em
s
(6
m
ul
tip
le
ch
oi
ce
an
d
10
tr
ue
/
fa
ls
e)
[4
8]
Su
m
of
co
rr
ec
t
an
sw
er
s
Ba
se
lin
e,
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
Bu
rd
en
of
sc
re
en
in
g
on
pa
tie
nt
Re
vi
ew
pa
tie
nt
’s
EM
R
fo
r
ad
di
tio
na
ld
ia
gn
os
tic
pr
oc
ed
ur
es
du
e
to
fa
ls
e-
po
si
tiv
e
re
su
lts
,
id
en
tif
ic
at
io
n
of
an
ab
no
rm
al
ity
on
sc
re
en
in
g
ex
am
bu
t
fu
rt
he
r
w
or
k-
up
de
cl
in
ed
,i
de
nt
ifi
ca
tio
n
of
a
cl
in
ic
al
ly
un
im
po
rt
an
t
ca
nc
er
;d
oc
um
en
ta
tio
n
of
de
pr
es
si
ve
sy
m
pt
om
s,
an
xi
et
y,
or
pa
in
re
la
te
d
to
th
e
sc
re
en
in
g
ex
pe
rie
nc
e
Ye
s
or
no
15
-
an
d
24
-m
on
th
fo
llo
w
-u
ps
Pa
tie
nt
EM
R
Bu
rd
en
of
sc
re
en
in
g
on
ca
re
gi
ve
r
M
ea
su
re
pe
rc
ep
tio
ns
ab
ou
t
th
e
bu
rd
en
of
th
e
m
am
m
og
ra
ph
y
fo
r
th
e
pa
tie
nt
;s
em
i-s
tr
uc
tu
re
d
q
ue
st
io
ns
ab
ou
t
pa
tie
nt
’s
m
am
m
og
ra
m
ex
pe
rie
nc
e
an
d
pe
rc
ei
ve
d
bu
rd
en
of
sc
re
en
in
g
D
es
cr
ip
tiv
e
15
-m
on
th
fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
;
pa
tie
nt
re
po
rt
ed
Ro
le
in
de
ci
si
on
-m
ak
in
g
A
ss
es
se
s
pr
ef
er
en
ce
s
fo
r
an
d
in
vo
lv
em
en
t
in
m
ak
in
g
de
ci
si
on
s
on
th
ei
r
ow
n
or
sh
ar
in
g
re
sp
on
si
bi
lit
y
w
ith
th
ei
r
fa
m
ily
or
do
ct
or
[7
1]
A
ct
iv
e
vs
.p
as
si
ve
/
sh
ar
ed
w
ith
do
ct
or
(s
in
ce
ai
m
of
de
ci
si
on
ai
ds
is
to
he
lp
dy
ad
s
be
m
or
e
ac
tiv
e
in
de
ci
si
on
-
m
ak
in
g)
Fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
;
pa
tie
nt
re
po
rt
ed
A
cc
ep
ta
bi
lit
y
of
th
e
m
at
er
ia
ls
A
ss
es
s
ca
re
gi
ve
rs
’a
nd
pa
tie
nt
s’
pe
rc
ep
tio
ns
ab
ou
t
th
e
le
ng
th
,c
la
rit
y,
an
d
he
lp
fu
ln
es
s
of
th
e
de
ci
si
on
ai
d
an
d
th
ei
r
w
ill
in
gn
es
s
to
re
co
m
m
en
d
it.
Th
e
nu
m
be
r
of
tim
es
th
ey
re
vi
ew
ed
it,
ho
w
m
an
y
pa
ge
s
th
ey
re
ad
,
ho
w
lo
ng
it
to
ok
th
em
to
re
ad
it,
ho
w
th
ey
w
ou
ld
pr
ef
er
to
re
ce
iv
e
it
if
no
t
pa
rt
of
a
st
ud
y
D
es
cr
ip
tiv
e
Fo
llo
w
-u
p
C
ar
eg
iv
er
re
po
rt
ed
;
pa
tie
nt
re
po
rt
ed
Fowler et al. Trials          (2018) 19:678 Page 6 of 12
is in their ability to make an informed medical decision
[63]. We will use the DSE to measure caregiver
decision-making self-efficacy for mammography deci-
sions for their relative with ADRD. To measure the
change in self-efficacy over time in both groups, we will
measure it at two time points [63]. In previous studies,
the psychometric properties of the DSE had an alpha co-
efficient of 0.92 [64].
Other measures include the intention to be screened
as well as the burden of screening on the patient and
caregiver. Intentions to be screened will be examined
using one item on a 5-point scale and another categor-
ical item that asks how many more mammograms the
patient and caregiver think that the patient will get in
her lifetime. We will categorize scores as 1–2 (no), 3
(unsure), or 4–5 (yes) [48, 65]. Knowledge about mam-
mograms for older women with ADRD will be measured
with a 16-item measure mapped directly from the infor-
mation presented in the decision aid [48]. We also will
collect data on the role of the patient and caregiver in
the decision about mammography, if a decision oc-
curred, and assess the extent to which each member of
the dyad participated in the review of the decision aid
through the semi-structured interviews. This will allow
us to describe differences in the roles of the patient and
caregiver in decision-making among different dyads.
Perceptions of the burden of screening on the care-
giver will be determined using structured questions
about the mammogram experience. Additionally, the
burden of screening on the patient will be evaluated by
reviewing the patient’s EMR for additional diagnostic
procedures due to false-positive results; identification of
an abnormality on the screening exam but further
work-up declined; identification of a clinically unimport-
ant cancer; and documentation of depressive symptoms,
anxiety, or pain related to the screening experience.
Data monitoring
The data safety monitoring plan for this trial will be
monitored by the principal investigator and a
four-member data safety and monitoring board. The
board’s charter contains a detailed list of the board’s re-
sponsibilities. The board will act in an advisory capacity
to the institutional review board and a National Institute
on Aging program official and it will monitor participant
safety and evaluate the progress of the study. It will re-
view the procedures for maintaining the confidentiality
of the data and review the quality of data collection,
management, and analyses.
Potential adverse events, such as new breast cancer
diagnoses, complications of receiving a mammogram,
complications from surgical or medical treatment fol-
lowing an abnormal mammogram, or distress related to
receiving a mammogram, will be monitored continually
by the DECAD research manager and discussed weekly
by the research team. All adverse events and unantici-
pated problems will be reported to the study’s principal
investigator within 24 h. If unanticipated serious adverse
events occur (i.e., those not of a type listed in the data
and safety monitoring plan) that are related to the inter-
vention, they will be reported within 48 h of the study
team’s learning of them.
Data collection
Data for the DECAD trial will be collected at baseline, at
the follow-up after the index PCP visit, and at 15 and
24 months following the intervention. Following the
confirmation of eligibility and after providing informed
consent, the caregivers in both arms will complete the
baseline assessment, which includes the DCS and DSE,
intention to allow screening, severity of cognitive impair-
ment using the dementia severity rating scale [66],
knowledge [48], health literacy based on the short test of
functional health literacy in adults (S-TOFHLA) [67],
and numeracy based on the subjective numeracy scale
[68]. Patient baseline assessments include intention to
undergo screening, and their attitudes, norms, and expe-
riences with mammograms. Research staff who adminis-
ter the follow-up assessments will be blinded to dyad
intervention status and they will be trained to read all
questionnaires verbatim and not to add commentary.
In addition to the primary and secondary measures,
we will collect social and demographic data on all pa-
tients and caregivers, including age, sex, and race. We
also will collect the relationship of the caregiver to the
patient, frequency and type of contact with the patient,
geographic distance from the patient, education level,
annual income, self-reported health status, severity of
cognitive impairment with the dementia severity rating
scale [66], the degree of functional impairment, and how
bothersome or upsetting that impairment is to the care-
giver using the caregiver assessment of function and
upset tool [69]. Additional descriptive data regarding the
patient will be obtained from recruitment site databases
and the INPC including, but not limited to, date of
ADRD diagnosis and co-morbidities.
Data will be collected face-to-face at the clinic, in the
caregivers’ or patients’ home, or via telephone. Data will
also be obtained from the EMR. All survey data will be en-
tered into a database using Research Electronic Data Cap-
ture (REDCap), a secure web application available through
our Clinical and Translational Science Institute [13].
Timeline
The recruitment of patients started on 1 December 2017
and is expected to be finalized by December 2020. All data
from all follow-ups is expected to be collected by 2022.
The data analysis, writing of scientific manuscripts, and
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submissions to peer-reviewed scientific journals will be
carried out during 2021, 2022, and 2023. Figure 2 is the
schedule of enrollment, interventions, and assessments.
Analysis plan
Study arm comparison
We will examine univariate distributions of continuous
variables to detect any potential violations of the as-
sumptions in our planned parametric method of ana-
lysis. We will transform variables as needed to ensure
normal distribution assumptions are met. We will use
nonparametric methods if the transformations are inad-
equate. Th demographic characteristics of the patients
and caregivers will be compared to evaluate if the two
groups are effectively balanced. We will use chi-squared
tests or Fisher’s exact tests to compare the frequencies
of categorical variables. Analysis of variance (ANOVA),
or its nonparametric alternative, the Wilcoxon rank sum
test, will be used to compare the distribution of continu-
ous variables between the groups.
Analysis of covariance (ANCOVA) models will be used
to compare mean DCS scores between the intervention
and control groups. For each caregiver, the difference in
DCS scores from baseline to follow-up will be used as
the dependent variable in ANCOVA with randomization
group assignment as the independent variable and other
potential baseline covariates that are found to be signifi-
cantly different between the two groups in the univariate
comparisons. ANCOVA models will also be used to
compare changes in decision-making self-efficacy and
intention to screen at follow-up between the interven-
tion and control groups after adjusting for site and other
potential baseline covariates found to be significantly dif-
ferent between the two groups in the univariate
comparisons.
A binary indicator for receipt of mammograms within
24 months from the intervention date will be tested in a
Fig. 2 Schedule of enrollment, interventions, and assessments
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logistic regression model. The group (decision aid or
control) and other potential baseline covariates found to
be different in the univariate comparisons will be used
as the independent variable.
Subgroup analyses will be used for both the primary and
secondary outcomes, examining any potential moderating ef-
fect of patients’ and caregivers’ characteristics on decision aid
impact. Likelihood ratio tests in mixed effect models will be
used to determine whether there are significant clustering ef-
fects due to physicians. Mixed effects adjustments for phys-
ician effects will be used in the presence of significant
clustering effects. The following patient variables will be in-
cluded in subgroup analyses: age, level of cognitive impair-
ment, level of functional impairment, number of
co-morbidities, and their role in mammography decisions.
The following caregiver variables will be included in sub-
group analyses: relationship to the patient, level of education,
level of bother or upset by patient functional impairments,
and perceived burden of mammography for the patient and
for them at baseline. We will include each of these variables
in the ANCOVA models for the primary outcome (caregiver
decisional confect) and in the logistic models for the second-
ary outcomes (caregiver decision-making self-efficacy,
intention to screen, and patient receipt of mammogram),
and test for interactions between these variables and the
intervention group adjusting for recruitment sites and other
potential baseline covariates. Significant interaction between
a patient/caregiver characteristic variable and group would
indicate different intervention effects in the dyad subgroups
defined by the variable. We will use SAS 9.4 for all analyses
(SAS Institute, Carey, NC).
An analysis of the semi-structured qualitative data
from the 15-month caregiver assessments will begin
after each assessment is completed to refine the data
collection process and to identify and pursue emergent
themes for subsequent caregiver interviews. Interviews
will be conducted by telephone, unless the caregiver re-
quests an in-person interview, and will be audio-re-
corded and transcribed verbatim. Two independent
coders will code each set of responses and a three-step
coding process derived from the sociological tradition of
grounded theory will be used to analyze the recorded in-
terviews [70]. Data from the qualitative interviews will
enhance the findings from the primary and secondary
outcomes of the trial by adding nuanced information
from the caregiver about how they used the decision aid,
details of any discussions or decisions about mammo-
grams, their experience of the patient receiving a mam-
mogram, and their perception of the patient’s experience
in arranging to have a mammogram.
Justification of sample size
The sample size for the proposed trial was calculated
using our pilot data, which showed effect sizes of 0.28
on DCS score and 0.34 for self-efficacy scores. To detect
an effect size of 0.28 or greater on DCS scores between
the two groups, we will need to have 202 patient/care-
giver dyads per group to complete both baseline and
follow-up with 80.2% power using a two-sample t-test at
0.05 level. Allowing for 5% missing data at the
follow-up, we will need to enroll 213 patient/caregiver
dyads per group (total enrollment of 426). With our
planned sample size, we will have 92.6% power to detect
an effect size of 0.34 or greater on changes in
self-efficacy scores between the two groups.
Using EMR data from the recruitment sites in this
trial, we identified 9588 women who are ≥75 years and
who had had a mammogram in the last 5 years, resulting
in an estimated mammogram screening rate of 27.5% in
our patient population. In detecting a change in the up-
take of mammograms, 213 patient/caregiver dyads per
group will have 80% power to detect a 42% reduction in
the screening rate (27.5% in the control group and 15.9%
in the decision aid group) using Fisher’s exact test at α =
0.05. For the exploratory aim, assuming equal sample
sizes in the two subgroups and screening rates in the
control group stay at 27%, we will have 80% power to
detect a screening rate of 11.5% (a reduction of 58%) in
one subgroup and a screening rate of 22% (reduction of
20%) in the other subgroup using Fisher’s exact test at
0.05 significance level.
Discussion
The benefits and harms of mammograms for older
women are not known, as no randomized controlled
trial has included women with ADRD who are ≥75 years
[23, 37, 71]. In part because of this lacuna, guidelines on
mammography screening in older women vary [5–12]
(http://www.choosingwisely.org/clinician-lists/amda-can-
cer-screenings-if-life-expectancy-less-than-10-years/).
The DECAD study is the only randomized controlled
trial of a decision aid to support ADRD caregivers in de-
ciding on cancer screening, which is a common decision
in primary care. If the DECAD trial is successful, the re-
sults may also inform the development of other decision
aids for ADRD caregivers in primary-care settings, ad-
dressing other cancer screening tests, such as a colonos-
copy, or other treatments of questionable value for
patients with ADRD.
The DECAD study is methodologically innovative in
that it will test a new paradigm for shared
decision-making that involves the patient/caregiver dyad.
Specifically, the proposed work will extend the shared
decision-making of the caregiver to a dynamic model that
is responsive to the communication and decision-making
needs of the surrogates of patients with ADRD. As part of
the DECAD study, we will measure both the caregivers’
role and the patients’ role in decision-making about
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mammograms and the burden of mammograms from
their perspective. Also, we will test the effect of ADRD se-
verity on the use of the decision aid. Results from DECAD
will be extended to help us learn how to present the sig-
nificant risks of medical interventions, in general, to both
ADRD patients and caregivers, which is essential for pro-
viding high-quality cost-effective care.
The DECAD trial has some limitations. The interven-
tion is intended to promote and enhance shared
decision-making between caregivers of women with
ADRD and the women’s PCP, but the study does not
interact directly with PCPs. We considered an alterna-
tive design where both the caregiver and the PCP receive
the decision aid but decided to measure the decision
aid’s effectiveness on the patient/caregiver dyad since the
decision aid was designed for caregivers. If we detect a
significant clustering effect due to physician, we will
analyze the data using mixed effects models to adjust for
physician clustering. This will lead to a lower power than
what we presented in our power estimates. Additionally,
regarding possible contamination, there may be situa-
tions where some of the content in our decision aid is
made available to dyads in the control group through in-
teractions with physicians or through other channels.
However, our decision aid presents specific and focused
data about mammograms in the context of older women
with ADRD, and our trial is designed to detect differ-
ences in outcomes between the two randomized groups.
In situations with moderate contamination rates, it has
been shown that individualized randomization can be
more efficient in terms of sample size compared to clus-
ter randomization [72].
To minimize any impact, we will stratify randomization
by site. Lastly, given the nature of the intervention, blind-
ing of the dyad is not possible. However, research assis-
tants who collect post-PCP outcome assessments are
blinded to each dyad’s allocation and are trained to admin-
ister the assessments the same to all dyads and without
any indication of randomization group.
In conclusion, DECAD is an evaluation of a decision
aid intervention for ADRD caregivers with high poten-
tial to be implemented into primary care. Given the
inherent complexities of caring for persons with
ADRD in primary care and the frequency of caregiver
participation in medical decisions, we anticipate that
the use of decision aids will facilitate quality decisions
regarding mammography screening. The decrease in
the use of cancer screening tests in some patients with
ADRD will reduce the burden on both the patient and
caregiver and change the practice and behavior with
respect to cancer screening. The results from this
study will inform other interventions that support
ADRD caregivers’ decision-making around other types
of medical care and treatment and that are tailored to
match the ADRD patient’s life expectancy and goals of
care.
Trial status
This protocol was registered in ClinicalTrial.gov under
identifier NCT03282097 on 13 September 2017 and the
last update was made on 21 November 2017. The
current protocol is version 2, dated 24 May 2018. Re-
cruitment started on 1 December 2017 and is expected
to be complete by December 2022. This trial is currently
in the patient selection and intervention stages. To date,
100 patient/caregiver dyads have been enrolled, none of
whom have completed the trial.
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